AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31718957 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50mg
Number of subjects: 568
Study 31718957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 568
Study 29566659 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose, high-frequency (LDHF) training approach
Number of subjects: 403
Study 28270187 — intervention group
Group type: EXPERIMENTAL
Intervention: HICS treatment
Number of subjects: 20
Study 28270187 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 24480615 — intervention group
Group type: EXPERIMENTAL
Intervention: Zurich Resource Model (ZRM) training
Number of subjects: 60
Study 24480615 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 24177175 — intervention group
Group type: EXPERIMENTAL
Intervention: Research questionnaire included with FOBt kit
Number of subjects: 47774
Study 24177175 — intervention group
Group type: COMPARATOR
Intervention: No research questionnaire included with FOBt kit
Number of subjects: 47774
Study 24177175 — intervention group
Group type: EXPERIMENTAL
Intervention: Research questionnaire sent 2-3 days after FOBt kit
Number of subjects: 47774
Study 24177175 — intervention group
Group type: COMPARATOR
Intervention: No research questionnaire sent 2-3 days after FOBt kit
Number of subjects: 47774
Study 21167587 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitadur Alpha discs
Number of subjects: 120
Study 21167587 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS e.max Ceram discs
Number of subjects: 120
Study 18716854 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling intervention (modeling DVD)
Number of subjects: 20
Study 18716854 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 16520570 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of ketamine administered after induction of anesthesia, approximately 5 min prior to surgery
Number of subjects: 60
Study 16520570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ketamine)
Number of subjects: 60
Study 16520570 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of ketamine
Number of subjects: 60
Study 16520570 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 12697866 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human keratinocyte growth factor (KGF) at doses of 60 and 80 microg/kg/d
Number of subjects: 81
Study 12697866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 11063766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg orally, 3 times a day) during gentamicin therapy
Number of subjects: 32
Study 11063766 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gentamicin and placebo)
Number of subjects: 32
Study 11063766 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine and Placebo
Number of subjects: 32
Study 9594199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwashed shed mediastinal blood (group 1)
Number of subjects: 42
Study 9594199 — intervention group
Group type: COMPARATOR
Intervention: Banked blood (group 2)
Number of subjects: 42
Study 1343614 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surfactant (colfosceril palmitate, Exosurf)
Number of subjects: 420
Study 1343614 — intervention group
Group type: COMPARATOR
Intervention: Selective surfactant (air placebo)
Number of subjects: 420
Study 6504920 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study 6504920 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30837403 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconium oxide sand-blasting (Group A)
Number of subjects: 50
Study 30837403 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia bonded porcelain (Group B)
Number of subjects: 50
Study 30837403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot-etching solution (Group C)
Number of subjects: 50
Study 30837403 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment zirconia (Group D)
Number of subjects: 50
Study 30837403 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment nickel-chromium alloy (Group E)
Number of subjects: 50
Study 29898704 — intervention group
Group type: COMPARATOR
Intervention: Continuous cycling exercise at moderate intensity (experiment A)
Number of subjects: 15
Study 29898704 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cycling exercise plus Flutter(R) (experiment B)
Number of subjects: 15
Study 27882012 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training Group (RTG)
Number of subjects: 14
Study 27882012 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 14
Study 25454968 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40
Study 25454968 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 40
Study 22023910 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental food preparers attended 8 weekly interactive lessons
Number of subjects: 100
Study 22023910 — intervention group
Group type: COMPARATOR
Intervention: Control food preparers received 8 weekly mailings with similar recipes and handouts
Number of subjects: 100
Study 19616304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 179
Study 19616304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 17590217 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 569
Study 17590217 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 569
Study 17590217 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 600 mg
Number of subjects: 569
Study 17590217 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 569
Study 17590217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 569
Study 15714224 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (0.5 mg at 1700 h for 6 days)
Number of subjects: 29
Study 15714224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15714224 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Number of subjects: 29
Study 12357730 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0
Study 12357730 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 12357730 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 0
Study 9788075 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related functional magnetic resonance imaging (ER-fMRI)
Number of subjects: 0
Study 9101094 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dobutamine infusion (6 micrograms/kg/min from 10 minutes before induction of anaesthesia till the fifth postoperative hour)
Number of subjects: 12
Study 9101094 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dobutamine infusion)
Number of subjects: 12
Study 2649996 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose piperacillin
Number of subjects: 214
Study 2649996 — intervention group
Group type: COMPARATOR
Intervention: Triple-dose cefoxitin
Number of subjects: 214
Study 2649996 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative anemia
Number of subjects: 214
Study 2649996 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 214
Study 31148908 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux plastic stent (ARPS)
Number of subjects: 38
Study 31148908 — intervention group
Group type: COMPARATOR
Intervention: Traditional plastic stent (TPS)
Number of subjects: 38
Study 31148908 — intervention group
Group type: EXPERIMENTAL
Intervention: ARPS
Number of subjects: 38
Study 31148908 — intervention group
Group type: COMPARATOR
Intervention: TPS
Number of subjects: 38
Study 31148908 — intervention group
Group type: EXPERIMENTAL
Intervention: ARPS and TPS
Number of subjects: 38
Study 28253257 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning covering 25% of a cigarette pack
Number of subjects: 5014
Study 28253257 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning covering 50% of a cigarette pack
Number of subjects: 5014
Study 28253257 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning covering 75% of a cigarette pack
Number of subjects: 5014
Study 26283175 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemonetics MCS(®) + cell separator
Number of subjects: 526
Study 23722616 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 (indacaterol 110 μg/glycopyrronium 50 μg)
Number of subjects: 2144
Study 23722616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2144
Study 21385863 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg daily
Number of subjects: 264
Study 21385863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 19663520 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib followed by valdecoxib
Number of subjects: 1062
Study 19663520 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1062
Study 16505409 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 400 mg intramuscularly (single dose)
Number of subjects: 218
Study 16505409 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine 37.5 mg per day for one week, then 75 mg per day
Number of subjects: 218
Study 12765455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Number of subjects: 207
Study 10871979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast titration (every 2 weeks)
Number of subjects: 2935
Study 10871979 — intervention group
Group type: COMPARATOR
Intervention: Slow titration (every 6 weeks)
Number of subjects: 2935
Study 9201043 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 to 200 micrograms/kg/min) administered to increase cardiac index and DO2 until all therapeutic goals were achieved.
Number of subjects: 78
Study 9201043 — intervention group
Group type: COMPARATOR
Intervention: Control group received dobutamine only if cardiac index was < 2.8 L/min/m2.
Number of subjects: 78
Study 8253948 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-culture with a confluent monolayer of Vero cells
Number of subjects: 100
Study 8253948 — intervention group
Group type: COMPARATOR
Intervention: Standard culture without Vero cells
Number of subjects: 100
Study 3942892 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 3942892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30335633 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 20
Study 30335633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27751960 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS SHOULDER montage
Number of subjects: 9
Study 27751960 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS HEAD montage
Number of subjects: 9
Study 27751960 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9
Study 27751960 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SHAM)
Number of subjects: 9
Study 27751960 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (including CON and SHAM)
Number of subjects: 9
Study 24894310 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated mental health care programme
Number of subjects: 250
Study 24894310 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 250
Study 24904785 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol the night before surgery
Number of subjects: 88
Study 24904785 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol on the day of surgery
Number of subjects: 88
Study 24904785 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol the night and on the day of surgery
Number of subjects: 88
Study 24904785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 20147743 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-cyclophosphamide (AC) followed by docetaxel (Doc)
Number of subjects: 257
Study 20147743 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin-pemetrexed (AP) followed by docetaxel (Doc)
Number of subjects: 257
Study 20147743 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms combined
Number of subjects: 257
Study 18580181 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with a 1.5 mg/kg intravenous bolus in 10 min followed by a 1.5 mg . kg . h intravenous infusion
Number of subjects: 60
Study 18580181 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study 16086467 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Medicine (CM) interventions
Number of subjects: 662
Study 16086467 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and Alternative Medicine (CAM) interventions
Number of subjects: 662
Study 12461659 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of azathioprine and prednisone (NoCsA group, n=58)
Number of subjects: 117
Study 12461659 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine, azathioprine, and prednisone (CsA group, n=59)
Number of subjects: 117
Study 10066996 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 10066996 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 0
Study 10066996 — intervention group
Group type: COMPARATOR
Intervention: Younger normal control children (Control)
Number of subjects: 0
Study 8822109 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallbladder carcinoma and adenoma
Number of subjects: 45
Study 8822109 — intervention group
Group type: EXPERIMENTAL
Intervention: Common bile duct carcinoma
Number of subjects: 45
Study 8822109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampullary carcinoma
Number of subjects: 45
Study 8822109 — intervention group
Group type: COMPARATOR
Intervention: Gallbladder dysplasia
Number of subjects: 45
Study 8822109 — intervention group
Group type: COMPARATOR
Intervention: Chronic cholecystitis
Number of subjects: 45
Study 8822109 — intervention group
Group type: COMPARATOR
Intervention: Ampullary carcinoma in situ (CIS)
Number of subjects: 45
Study 2041848 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified breast biopsy technique
Number of subjects: 40
Study 2041848 — intervention group
Group type: COMPARATOR
Intervention: Manufacturer's method
Number of subjects: 40
Study 2041848 — intervention group
Group type: COMPARATOR
Intervention: Third technique
Number of subjects: 40
Study 7012883 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose physostigmine
Number of subjects: 9
Study 7012883 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 9
Study 30669360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracenomycin X (Tcm X)
Number of subjects: 0
Study 28688497 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis prevention education and counseling program (4-week education + 24-week counseling)
Number of subjects: 73
Study 25323219 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone (3 mg)
Number of subjects: 79
Study 25323219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 23561637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation at a dose of 1000 U/day for 12 months
Number of subjects: 47
Study 23561637 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 47
Study 23561637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 47
Study 21289621 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 209
Study 21289621 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 209
Study 19231253 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE graft
Number of subjects: 228
Study 19231253 — intervention group
Group type: COMPARATOR
Intervention: Dacron graft
Number of subjects: 228
Study 16849623 — intervention group
Group type: EXPERIMENTAL
Intervention: pegaptanib 0.3 mg intravitreous injection every 6 weeks for 48 weeks
Number of subjects: 0
Study 16849623 — intervention group
Group type: COMPARATOR
Intervention: sham injection (placebo)
Number of subjects: 0
Study 15545697 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam composite dressing
Number of subjects: 107
Study 15545697 — intervention group
Group type: COMPARATOR
Intervention: Hydrocellular foam dressing
Number of subjects: 107
Study 11747282 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined glucose plus fructosamine testing group (11 patients)
Number of subjects: 25
Study 11747282 — intervention group
Group type: COMPARATOR
Intervention: Glucose-only testing group (14 patients)
Number of subjects: 25
Study 9355897 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T (≤0.10 μg/L)
Number of subjects: 516
Study 9355897 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin I (>2.0 μg/L)
Number of subjects: 516
Study 8221482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy schedule of 4000 cGy in 15 or 16 fractions over 3 weeks plus a local boost of 1250 cGy to the primary site in 5 fractions over 1 week
Number of subjects: 551
Study 8221482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy schedule of 4000 cGy in 15 or 16 fractions over 3 weeks plus a local boost of 1000 cGy to the primary site in 4 or 5 fractions over 1 week
Number of subjects: 551
Study 8221482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy schedule of 5000 cGy in 25 fractions to the whole breast in 5 weeks, without a boost
Number of subjects: 551
Study 3713154 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (3 sets of 10 depth jumps, 3 days/week for 12 weeks)
Number of subjects: 26
Study 3713154 — intervention group
Group type: COMPARATOR
Intervention: Regular basketball training (control group)
Number of subjects: 26
Study 31738447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 26
Study 31738447 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 26
Study 29198641 — intervention group
Group type: EXPERIMENTAL
Intervention: HED-SMART (self-management training program)
Number of subjects: 235
Study 29198641 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 235
Study 26535563 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal endosheath endoscopy (TEE)
Number of subjects: 25
Study 26535563 — intervention group
Group type: COMPARATOR
Intervention: Standard endoscopy
Number of subjects: 25
Study 23578719 — intervention group
Group type: EXPERIMENTAL
Intervention: QCT-derived structural geometry measurements
Number of subjects: 237
Study 23578719 — intervention group
Group type: COMPARATOR
Intervention: DXA-derived structural geometry measurements
Number of subjects: 237
Study 23578719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-calibration using 4 measures (areal bone mineral density, W, standard deviation of normalized mineral mass projection profile distribution, displacement between center of mineral mass and geometric center)
Number of subjects: 237
Study 23025450 — intervention group
Group type: EXPERIMENTAL
Intervention: Kali phos 6x
Number of subjects: 86
Study 23025450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 21388579 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (3 mg twice a day, for 8 weeks)
Number of subjects: 20
Study 21388579 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation treatment only (No-RIV)
Number of subjects: 20
Study 18663301 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% fluoride gel
Number of subjects: 36
Study 18663301 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% fluoride gel
Number of subjects: 36
Study 18663301 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 36
Study 15673379 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of atrial fibrillation (AF)
Number of subjects: 45
Study 12853193 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (target dose 25 mg twice daily)
Number of subjects: 3029
Study 12853193 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (target dose 50 mg twice daily)
Number of subjects: 3029
Study 11173778 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 14
Study 9009677 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid for 14 days/amoxycillin 1000 mg bid for 14 days/tinidazole 500 mg bid for 14 days (Group A)
Number of subjects: 132
Study 9009677 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid for 14 days/amoxycillin 1000 mg bid for 14 days (Group B)
Number of subjects: 132
Study 9009677 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid for 14 days/azithromycin 500 mg/day for 3 days for 2 consecutive weeks (Group C)
Number of subjects: 132
Study 9009677 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day for 7 days/clarithromycin 250 mg bid for 7 days/tinidazole 500 mg bid for 7 days (Group D)
Number of subjects: 132
Study 1386523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 1 mg
Number of subjects: 982
Study 1386523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 982
Study 1386523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg
Number of subjects: 982
Study 1386523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 982
Study 6828338 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 600 mg
Number of subjects: 25
Study 6828338 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 600 mg
Number of subjects: 25
Study 6828338 — intervention group
Group type: COMPARATOR
Intervention: Lactose (placebo)
Number of subjects: 25
Study 30829714 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model for predicting cardiac rupture after acute myocardial infarction
Number of subjects: 577